Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Study of Redirected Autologous T Cells With a Claudin18.2-targeted Chimeric Antigen Receptor in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma

Trial Profile

Clinical Study of Redirected Autologous T Cells With a Claudin18.2-targeted Chimeric Antigen Receptor in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2018

At a glance

  • Drugs CAR-CLD18-T-cells-Carsgen-Therapeutics (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Sep 2018 According to a CARsgen media release, data from this trial were presented at 2018 CAR-TCR Summit.
    • 07 Sep 2018 Results published in the CARsgen Media Release
    • 08 Mar 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top